Daiwa Securities Adjusts Gilead Sciences Price Target to $90 From $73
Gilead Sciences Is Maintained at Sector Perform by RBC Capital
Gilead Sciences Analyst Ratings
Gilead Sciences Initiated at Outperform by Wolfe Research
Wolfe Research Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $110
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Gilead Sciences Analyst Ratings
Gilead Sciences (GILD) Gets a Buy From TD Cowen
Citi Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $125
Raymond James Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $103
Gilead Sciences Is Maintained at Hold by Truist Securities
Gilead Sciences Analyst Ratings
Maxim Group Downgrades Gilead Sciences(GILD.US) to Hold Rating
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $95 to $105
Gilead Sciences: Strong Financial Performance and Promising Pipeline Drive Buy Rating
Gilead Sciences Is Maintained at Equal-Weight by Barclays
Gilead Sciences Price Target Raised to $95.00/Share From $84.00 by Barclays
Cantor Fitzgerald Sticks to Its Hold Rating for Gilead Sciences (GILD)
Gilead Sciences Analyst Ratings
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $95 to $105